GENENTA SCIENCE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 USD | -4.02% |
|
-10.74% | -37.37% |
| May. 06 | Genenta Science S.p.A. Announces New Board Appointments | CI |
| Apr. 08 | Genenta Science S.P.A. Announces Resignation of Board Members | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 52.43M 56.48M |
|---|---|---|---|---|---|
| Net income 2024 * | -18M -19.39M | Net income 2025 * | -24M -25.85M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.43
x | P/E ratio 2025 * |
-3.23
x | Employees | 14 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.75% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -4.02% | ||
| 1 week | -10.74% | ||
| Current month | +0.65% | ||
| 1 month | -10.56% | ||
| 3 months | -22.50% | ||
| 6 months | -42.74% | ||
| Current year | -37.37% |
1 week
3.10
4.22
1 month
2.204.22
Current year
2.204.96
1 year
2.206.81
3 years
2.2013.13
5 years
2.2013.13
10 years
2.2013.13
| Managers | Title | Age | Since |
|---|---|---|---|
Bernhard Gentner
FOU | Founder | - | 14-07-23 |
Luigi Naldini
FOU | Founder | - | 14-07-23 |
| Chief Executive Officer | 50 | 14-07-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 62 | 21-05-19 |
Roger Abravanel
BRD | Director/Board Member | 77 | 21-05-19 |
| Chief Executive Officer | 50 | 14-07-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 3.1 | -4.02% | 17,777 |
| 24-05-09 | 3.23 | -12.70% | 31,590 |
| 24-05-08 | 3.7 | +0.82% | 989 |
| 24-05-07 | 3.67 | +5.16% | 3,259 |
| 24-05-06 | 3.49 | +0.49% | 1,649 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotes
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.878
EUR
Average target price
21.36
EUR
Spread / Average Target
+642.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.37% | 56.47M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- GNTA Stock